Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
SIRP-α agonist antibody
US10618976B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10618976-B2 |
| Application number | US-201615577565-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 8, 2016 |
| Priority date | Jun 16, 2015 |
| Publication date | Apr 14, 2020 |
| Grant date | Apr 14, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods are provided relating to anti-SIRPα agonist antibodies. The antibodies of the invention bind to human SIRPα, and activate signaling, thereby inhibiting processes mediated by SIRPα, including without limitation phagocytosis. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRPα agonist antibodies; and cell lines that produce these antibodies.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated monoclonal antibody or fragment thereof that selectively binds to human SIRPα wherein the antibody comprises two variable regions, wherein one variable region comprises the CDR sequences set forth in SEQ ID NO:3, 4 and 5; and the other variable region comprises the CDR sequences set forth in SEQ ID NO:6, 7 and 8. 2. The antibody of claim 1 , wherein the antibody is a human monoclonal antibody. 3. The antibody or fragment of claim 1 , wherein the antibody is a variable region fragment. 4. The antibody or fragment of claim 1 , wherein the variable regions are present on a single polypeptide chain. 5. The antibody or fragment of claim 1 , wherein the variable regions are present on separate polypeptide chains. 6. The antibody of claim 5 , wherein the separate polypeptide chains are, respectively, a heavy chain and a light chain. 7. The antibody of claim 1 , comprising a heavy and light chain variable region sequence as set forth in SEQ ID NO:1 and SEQ ID NO:2.
Assignees
Inventors
Classifications
Complementarity determining region [CDR] · CPC title
- C07K16/2803Primary
against the immunoglobulin superfamily · CPC title
Agonist effect on antigen · CPC title
from primates, e.g. man · CPC title
- C07K16/42Primary
against immunoglobulins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10618976B2 cover?
- Compositions and methods are provided relating to anti-SIRPα agonist antibodies. The antibodies of the invention bind to human SIRPα, and activate signaling, thereby inhibiting processes mediated by SIRPα, including without limitation phagocytosis. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more o…
- Who is the assignee on this patent?
- Univ Leland Stanford Junior
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).